References – Envelta™

Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia

Lisa Godfrey, Antonio Iannitelli, Natalie L. Garrettc, Julian Moger, Ian Imbert, Tamara King, Frank Porreca, Ramesh Soundararajan, Aikaterini Lalats, Andreas G. Schätzlein, Ijeoma F. Uchegbu
Journal of Controlled Release

There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals.

We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids.

Currently, enkephalins are limited in their therapeutic potential by their pharmacokinetic profiles due to their inability to cross the blood-brain barrier to reach opioid receptors located in the central nervous system.

View PDF

Targeting Alternative Opioid Receptor Reduces Drug Side Effects

Sara E. Teller
Legal Reader

View PDF

Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain

Nestor N. Jimenez-Vargas, Jing Gong, Matthew J. Wisdom, Dane D. Jensen, Rocco Latorre, Alan Hegron, Shavonne Teng, Jesse J. DiCello, Pradeep Rajasekhar, Nicholas A. Veldhuis, Simona E. Carbone, Yang Yu, Cintya Lopez-Lopez, Josue Jaramillo-Polanco, Meritxell Canals, David E. Reed, Alan E. Lomax, Brian L. Schmidt, View ORCID ProfileKam W. Leong, Stephen J. Vanner, Michelle L. Halls, Nigel W. Bunnett, and Daniel P. Poole
National Academy of Sciences

View PDF

Leucine-Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models

Presented by Dr. Jeff Gudin at the 3rd Annual NIH HEAL Investigator Initiated Meeting

View PDF

Post Cancer Pain

Facts About Cancer Pain

From American Cancer Society

View Website

References – Probudur™

Prolonged analgesia from Bupisome and Bupigel formulations: From design and fabrication to improved stability

Rivka Cohen, Hiba Kanaan, Gilbert J. Grant, Yechezkel Barenholz
Journal of Controlled Release

Based on data from early animal studies, Probudur has indicated post-operative control for up to 96 hours, which is 24 hours longer than the leading product on the market. If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label.

View PDF

Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

Yaelle Bavli, Malcolm Rabie, Yakov Fellig, Yoram Nevo, and Yechezkel Barenholz

View PDF

References – Epoladerm™

Knee Osteoarthritis: A Primer

Michelle J Lespasio, DNP, JD, ANP; Nicolas S Piuzzi, MD; M Elaine Husni, MD, MPH; George F Muschler, MD; AJ Guarino, PhD; Michael A Mont, MD
Osteoarthritis Research Society International (OARSI)

A synopsis of the current medical understanding of knee osteoarthritis. The prevalence, causes and associated risk factors, symptoms, diagnosis
and classification, and treatment options are described in detail.

View PDF

Burden of OA submitted to FDA drives home seriousness of disease

Osteoarthritis Research Society International (OARSI)

OARSI submitted a white paper to the FDA that describes that changing climate of the OA treatment industry.

View PDF

Knee Osteoarthritis

American Academy of Orthopaedic Surgeons

Information on knee osteoarthritis including the causes and common treatments.

View PDF

References – AnQlar™

How COVID-19 Compromises Brain Function

Information on post-COVID-19 “brain fog”


“Plenty of patients get COVID-19, recover well and then a month or two later develop cognitive symptoms, such as slow thinking, difficulty concentrating and fatigue.”

View PDF

Long Covid

A Detailed Study of Patients with Long-Haul COVID

FAIR Health, Inc.

Using data from over 34 billion private healthcare claims, the prevalence of post-COVID conditions 30 days or more after initial diagnosis was compiled.

View PDF

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray

Krzysztof Pyrć, Aleksandra Milewska, Emilia Barreto Duran, Paweł Botwina, Rui Lopes, Alejandro Arenas-Pinto, Moutaz Badr, Ryan Mellor, Tammy L. Kalber, Delmiro Fernandes-Reyes, Andreas G. Schätzlein, Ijeoma F. Uchegbu

We hypothesise that preventing viral entry into mammalian nasal epithelial cells may be one way to limit the spread of COVID-19. We can show that the polymer GCPQ is able to reduce the infectivity of SARS-COV-2 and limit infectivity in human airway epithelial cells.

View PDF

References – VRP324

Forms of Rare Pediatric Epilepsy

The Evolving Nature of Lennox-Gastaut Syndrome and Dravet Syndrome

Greenwich Biosciences, Inc

View PDF

Patient-Centered Outcomes Research in Dravet Syndrome

Dravet Syndrome Foundation

View PDF